Experts in the field of CLL/SLL discussed the role of BTK inhibitors and degraders in R/R CLL/SLL during an OncLive Scientific Interchange and Workshop.
Next-Generation Decisions in CLL: Redefining BTK Inhibitors Across the Frontline and Relapsed Settings
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
3
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
4
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
5